Evidence map›Paper›PMID 36088887›Full record

ArticleClinics (Sao Paulo, Brazil)2022

Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series.

Regiane Saraiva de Souza Melo Alencar, Claudia P Oliveira, Aline Lopes Chagas, Leonardo Gomes da Fonseca, Claudia Maccali, Lisa Rodrigues da Cunha Saud, Mariana Pinheiro Xerfan, Jose Tadeu Stefano, Paulo Herman, Luiz Augusto Carneiro D'Albuquerque and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Regiane Saraiva de Souza Melo AlencarInstituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil; São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Claudia P OliveiraSão Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Laboratório de Gastroenterologia Clínica e Experimental (LIM-07), Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Aline Lopes ChagasInstituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil; São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Leonardo Gomes da FonsecaInstituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil; São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Claudia MaccaliInstituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil; São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Lisa Rodrigues da Cunha SaudInstituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil; São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Mariana Pinheiro XerfanInstituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil; São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Jose Tadeu StefanoSão Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Laboratório de Gastroenterologia Clínica e Experimental (LIM-07), Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Paulo HermanDigestive Surgery Division, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Luiz Augusto Carneiro D'AlbuquerqueLiver and Digestive Organ Transplantation Unit, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Venâncio Avancini Ferreira AlvesSão Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Flair Jose CarrilhoSão Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Laboratório de Gastroenterologia Clínica e Experimental (LIM-07), Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address: fjcarril@usp.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the present study was to evaluate the clinical features, Hepatocellular Carcinoma (HCC) screening, treatment modalities, and Overall Survival (OS) in a series of Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma (NAFLD-HCC) Brazilian patients.

methodsThis was a cross-sectional study at the Instituto do Cancer do Estado de São Paulo, at the Faculdade de Medicina da Universidade de São Paulo with the approval of the local research ethics committee. NAFLD patients with HCC diagnosed, from May 2010 to May 2019, were included.

resultsA total of 131 patients were included. Risk factors for NAFLD were present in 94.7% of the patients. Only 29% of patients were in the HCC screening program before diagnosis. HCC treatment was performed in 84.7% of patients. Cumulative survival at the end of the first year was 72%, second-year 52%, and fifth-year 32%. HCC screening before diagnosis was not significantly associated with higher cumulative survival. The independent factors associated with shorter general survival were BCLC C-D, p < 0.001, and the size of the largest nodule > 42 mm, p = 0.039.

conclusionsAlthough the efficacy of screening in our population regarding overall survival was hampered due to the sample size (29% had screening), BCLC stages C‒D and the size of the largest nodule larger than 42 mm were identified as independent factors of worse prognosis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseBrazilCross-Sectional StudiesHumansSurvival AnalysisHCC screening programHepatocellular carcinomaNon-alcoholic fatty liver diseaseOverall survivalTreatment

Identifiers

PMID36088887
PMCPMC9468355
OpenAlexW4295123919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.